Researchers have found that the Meningitis B vaccine provides no protection against gonorrhoea, undermining hopes that the jab could serve double duty in preventing the sexually transmitted infection. The study contradicts earlier preliminary findings that suggested the vaccine might offer some defence against the STI.
Health authorities in several countries, including the UK, have recommended MenB vaccination for men who have sex with men and other high-risk populations, partly based on optimism about potential cross-protection against gonorrhoea. This strategy emerged after observational data hinted the vaccine could reduce gonorrhoea cases in vaccinated groups.
The new research challenges that assumption directly. Scientists tested whether antibodies generated by MenB vaccination could neutralize gonorrhoea bacteria, finding no meaningful protection mechanism. The vaccine targets Neisseria meningitidis serogroup B, a different pathogen from Neisseria gonorrhoeae, the bacterium causing gonorrhoea.
Gonorrhoea remains a persistent public health challenge, with antibiotic resistance rising globally. Many strains now resist multiple drug classes, limiting treatment options. Health systems have pinned some hopes on vaccines as a preventative strategy, making the MenB findings particularly disappointing for disease control efforts.
The study does not call for halting MenB vaccination programs, which remain vital for preventing meningococcal disease. Rather, it signals that relying on MenB vaccination alone to curb gonorrhoea transmission is misguided. Public health officials will need to refocus prevention strategies on traditional approaches including safer sex practices, regular testing, and antibiotic stewardship as resistance develops.
The findings underscore the complexity of vaccine cross-protection and highlight the urgent need for dedicated gonorrhoea vaccine research.